All News

After use of nonpharmacological and multiple blood pressure lowering medications, uncontrolled blood pressure still may be present. Thus, potential for patient to be diagnosed with resistant hypertension.

Novo Nordisk announced the results of the ELLIPSE trial, which examined efficacy and safety and demonstrated superiority of liraglutide (Victoza) injection 1.8 mg vs placebo, in a presentation at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies (PAS) Annual Meeting in Baltimore, MD, on Sunday.

High levels of ‘bad’ cholesterol, also known as low-density lipoprotein cholesterol (LDL-C), increase patients' risk for serious CV events such as heart attack or stroke. Adults who experience a heart attack or stroke have an approximately 1 in t3 chance to have another CV event.

Why did this person develope renal failure?

Study demonstrates safety of oral immunotherapy for peanut allergy in large group of preschool-aged children.

Adults who experience a heart attack or stroke have an approximately 1 in t3 chance to have another cardiovascular event.

The new initiative, entitled “Remove the Risk,” is part of the agency’s continued efforts to address the nationwide opioid crisis and aims to help decrease unnecessary exposure to opioids and prevent addiction.

This is the first time that the FDA has approved a treatment for pediatric patients with SLE. Belimumab has been approved for use in adult patients since 2011. GSK’s application for belimumab use in pediatric patients was granted the FDA’s Priority Review designation.

Belimumab has been approved for use in adult patients since 2011, and GSK’s application for belimumab use in pediatric patients was granted the FDA’s Priority Review designation.

Etanercept-ykro (Eticovo) is the second etanercept biosimilar to be approved by the FDA, following Sandoz’s etanercept-szzs (Erelzi) in 2016

Samsung Bioepis’ etanercept-ykro (Eticovo) was approved to treat all of the indications of the reference product, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Last week, National Association of EMS Physicians members joined with other health care professionals on Capitol Hil to bring attention to the issue of drug shortages, as emergency medical facilities across the country are forced to severely restrict use of certain IV fluids, anti-nausea medications, airway management medications, and other essential emergency medications (EEMs).

The day aims to address the importance and urgency of properly disposing unused and expired medication.

According to Teva, this recall was initiated by detection of an impurity – N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) – found in 6 lots of active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited that is above the FDA’s interim acceptable exposure limit.

The COAST-X clinical trial program is evaluating ixekizumab across various population subsets of patients with axial spondyloarthritis.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

The mission of the Action Collaborative is to convene and catalyze public, private, and nonprofit stakeholders to develop, curate, and disseminate multisector solutions designed to reduce opioid misuse and improve outcomes for individuals, families, and communities affected by the opioid crisis.

The American Society of Health-Systems Pharmacists has launched an online continuing education program that serves as a preparatory course for BPS certification in sterile compounding.

An analysis showed increasing rates of medical marijuana use for individuals diagnosed with cancer over a 10-year period.

Investigators used a CRISPR technique to expose weaknesses in the acute myeloid leukemia enzyme that many drugs target.

Announcement positions specialty pharmacy group for continued growth.

One reason to recommend vitamin C is for skin health and chronic wound healing.

Top news of the day from across the health care landscape.

According to Purdue Pharma, Nalmefene HCl has a longer duration of action than naloxone, another opioid antagonist currently approved for emergency treatment of known or suspected opioid overdose.

Risankizumab-rzaa (Skyrizi, AbbVie) is indicated for adults with moderate-to-severe plaque psoriasis who are candidates for systemic or phototherapy.

The combination of selinexor and 4-OHT may be able to prevent endocrine resistance in hormone-responsive breast cancer by rewiring gene pathways.

In clinical trials, AbbVie's risankizumab-rzaa produced high rates of durable skin clearance – most people (82 and 81%) treated with the drug achieved 90% skin clearance (PASI 90) at 1 year, with the majority (56 and 60%) achieving complete skin clearance (PASI 100).

Top news of the day from across the health care landscape.

Research investigates whether statins are safe and effective for patients with inflammatory conditions, such as rheumatoid arthritis.